Efficacy and Safety of Different Bisphosphonates for Bone Loss Prevention in Kidney Transplant Recipients: A Network Meta-Analysis of Randomized Controlled Trials

Overview

Journal Chin Med J (Engl)

Specialty General Medicine

Date 2018 Mar 27

PMID 29578126

Authors

Yan Yang

Shi Qiu

Xi Tang

Xin-Rui Li

Ling-Hui Deng

Qiang Wei

Ping Fu

Affiliations

Soon will be listed here.

Abstract

Background: Mineral and bone disorder is one of the severe complications in kidney transplant recipients (KTRs). Previous studies showed that bisphosphonates had favorable effects on bone mineral density (BMD). We sought to compare different bisphosphonate regimens and rank their strategies.

Methods: We searched PubMed, Embase, and the Cochrane Central Register of Controlled Trials (CENTRAL) up to April 01, 2017, for randomized controlled trials (RCTs) comparing bisphosphonate treatments in adult KTRs. The primary outcome was BMD change. We executed the tool recommended by the Cochrane Collaboration to evaluate the risk of bias. We performed pairwise meta-analyses using random effects models and network meta-analysis (NMA) using Bayesian models and assessed the quality of evidence.

Results: A total of 21 RCTs (1332 participants) comparing 6 bisphosphonate regimens were included. All bisphosphonates showed a significantly increased percentage change in BMD at the lumbar spine compared to calcium except clodronate. Pamidronate with calcium and Vitamin D analogs showed improved BMD in comparison to clodronate with calcium (mean difference [MD], 9.84; 95% credibility interval [CrI], 1.06-19.70). The combination of calcium and Vitamin D analogs had a significantly lower influence than adding either pamidronate or alendronate (MD, 6.34; 95% CrI, 2.59-11.01 and MD, 6.16; 95% CrI, 0.54-13.24, respectively). In terms of percentage BMD change at the femoral neck, both pamidronate and ibandronate combined with calcium demonstrated a remarkable gain compared with calcium (MD, 7.02; 95% CrI, 0.30-13.29 and MD, 7.30; 95% CrI, 0.32-14.22, respectively). The combination of ibandronate with calcium displayed a significant increase in absolute BMD compared to any other treatments and was ranked best.

Conclusions: Our NMA suggested that new-generation bisphosphonates such as ibandronate were more favorable in KTRs to improve BMD. However, the conclusion should be treated with caution due to indirect comparisons.

References

Coco M, Glicklich D, Faugere M, Burris L, Bognar I, Durkin P . Prevention of bone loss in renal transplant recipients: a prospective, randomized trial of intravenous pamidronate. J Am Soc Nephrol. 2003; 14(10):2669-76. DOI: 10.1097/01.asn.0000087092.53894.80. View

Versele E, van Laecke S, Dhondt A, Verbeke F, Vanholder R, Van Biesen W . Bisphosphonates for preventing bone disease in kidney transplant recipients: a meta-analysis of randomized controlled trials. Transpl Int. 2015; 29(2):153-64. DOI: 10.1111/tri.12691. View

Shahidi S, Ashrafi F, Mohammadi M, Moeinzadeh F, Atapour A . Low-dose pamidronate for treatment of early bone loss following kidney transplantation: a randomized controlled trial. Iran J Kidney Dis. 2015; 9(1):50-5. View

Nayak B, Guleria S, Varma M, Tandon N, Aggarwal S, Bhowmick D . Effect of bisphosphonates on bone mineral density after renal transplantation as assessed by bone mineral densitometry. Transplant Proc. 2007; 39(3):750-2. DOI: 10.1016/j.transproceed.2007.01.065. View

Grotz W, Nagel C, Poeschel D, Cybulla M, Uhl M, Strey C . Effect of ibandronate on bone loss and renal function after kidney transplantation. J Am Soc Nephrol. 2001; 12(7):1530-1537. DOI: 10.1681/ASN.V1271530. View

Torregrosa J, Fuster D, Gentil M, Marcen R, Guirado L, Zarraga S . Open-label trial: effect of weekly risedronate immediately after transplantation in kidney recipients. Transplantation. 2010; 89(12):1476-81. DOI: 10.1097/TP.0b013e3181dc13d0. View

Salanti G, Higgins J, Ades A, Ioannidis J . Evaluation of networks of randomized trials. Stat Methods Med Res. 2007; 17(3):279-301. DOI: 10.1177/0962280207080643. View

Perazella M, Markowitz G . Bisphosphonate nephrotoxicity. Kidney Int. 2008; 74(11):1385-93. DOI: 10.1038/ki.2008.356. View

Kan S, Ning G, Chen L, Zhou Y, Sun J, Feng S . Efficacy and Safety of Bisphosphonates for Low Bone Mineral Density After Kidney Transplantation: A Meta-Analysis. Medicine (Baltimore). 2016; 95(5):e2679. PMC: 4748922. DOI: 10.1097/MD.0000000000002679. View

10.

Higgins J, Jackson D, Barrett J, Lu G, Ades A, White I . Consistency and inconsistency in network meta-analysis: concepts and models for multi-arm studies. Res Synth Methods. 2015; 3(2):98-110. PMC: 4433772. DOI: 10.1002/jrsm.1044. View

11.

Higgins J, Thompson S, Deeks J, Altman D . Measuring inconsistency in meta-analyses. BMJ. 2003; 327(7414):557-60. PMC: 192859. DOI: 10.1136/bmj.327.7414.557. View

12.

Lan G, Peng L, Xie X, Peng F, Wang Y, Yu S . Alendronate is effective to treat bone loss in renal transplantation recipients. Transplant Proc. 2008; 40(10):3496-8. DOI: 10.1016/j.transproceed.2008.09.034. View

13.

Kibret T, Richer D, Beyene J . Bias in identification of the best treatment in a Bayesian network meta-analysis for binary outcome: a simulation study. Clin Epidemiol. 2014; 6:451-60. PMC: 4259556. DOI: 10.2147/CLEP.S69660. View

14.

Adachi J, Bensen W, Brown J, Hanley D, Hodsman A, Josse R . Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis. N Engl J Med. 1997; 337(6):382-7. DOI: 10.1056/NEJM199708073370603. View

15.

Schwarz C, Mitterbauer C, Heinze G, Woloszczuk W, Haas M, Oberbauer R . Nonsustained effect of short-term bisphosphonate therapy on bone turnover three years after renal transplantation. Kidney Int. 2003; 65(1):304-9. DOI: 10.1111/j.1523-1755.2004.00369.x. View

16.

DerSimonian R, Laird N . Meta-analysis in clinical trials revisited. Contemp Clin Trials. 2015; 45(Pt A):139-45. PMC: 4639420. DOI: 10.1016/j.cct.2015.09.002. View

17.

Walsh S, Altmann P, Pattison J, Wilkie M, Yaqoob M, Dudley C . Effect of pamidronate on bone loss after kidney transplantation: a randomized trial. Am J Kidney Dis. 2009; 53(5):856-65. DOI: 10.1053/j.ajkd.2008.11.036. View

18.

Nam J, Moon J, Chung S, Kim S, Park K, Song Y . Pamidronate and calcitriol trial for the prevention of early bone loss after renal transplantation. Transplant Proc. 2000; 32(7):1876. DOI: 10.1016/s0041-1345(00)01898-4. View

19.

Koc M, Tuglular S, Arikan H, Ozener C, Akoglu E . Alendronate increases bone mineral density in long-term renal transplant recipients. Transplant Proc. 2002; 34(6):2111-3. DOI: 10.1016/s0041-1345(02)02872-5. View

20.

Cotte F, Fardellone P, Mercier F, Gaudin A, Roux C . Adherence to monthly and weekly oral bisphosphonates in women with osteoporosis. Osteoporos Int. 2009; 21(1):145-55. PMC: 2788149. DOI: 10.1007/s00198-009-0930-1. View